
A novel biomarker targeting early detection of Liver Cancer

CanAg Glypican-3 EIA





Find out more



Hepatocellular carcinoma

Liver cancer is a global health issue, and its incidence is progressively increasing worldwide. It has been estimated that every year more than 800,000 people are diagnosed with liver cancer globally¹, and that by 2025 this disease will affect more than 1 million individuals².

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer in adults, accounting for about 80% of cases (other forms include cholangiocarcinoma in 10–20% of cases and angiosarcoma in 1% of cases)³. In the majority of cases, HCC is a direct consequence of cirrhosis and chronic liver inflammation, and the major risk factors include HBV/HCV infection, heavy alcohol consumption, ingestion of aflatoxin B1, smoking, and nonalcoholic fatty liver disease (NAFLD) caused by obesity and insulin resistance⁴.

Surveillance of patients for early stage HCC may thus represent an effective tool for the improvement of patient's survival and effectiveness of treatment⁵. Specifically, early-stage HCC are eligible for curative therapies including ablation, surgical resection or liver transplantation, while patients diagnosed with late-stage disease are only eligible for palliative systemic therapies with poor response rates⁶.

In conclusion, there is an alarming (and unmet) clinical need for identifying highly sensitive and specific blood-biomarkers for the surveillance of high-risk subjects, for early detection of HCC and also for the prediction of therapeutic outcome. Ideally, the use of multiple biomarkers for early-stage HCC diagnosis might result in acceptable (> 80%) sensitivity without impacting specificity⁷.


Why test for Glypican-3?

- Increasing incidence of HCC in many countries Due to HCV, HBV, alcohol and obesity epidemic (fatty liver disease)
- Surveillance test for high risk patients could facilitate early detection of HCC
- Glypican-3 has emerged as a potential serological marker for early detection of HCC
- Initial studies indicates that Glypican-3 can increase sensitivity and specificity.
- Glypican-3 is a promising therapeutic target



Assay procedure

Below is an illustration of the CanAg Glypican-3 EIA two-step assay procedure. Results are available within 3.5 hours.



Glypican-3 Specification



Specifications Product No: 503-10

Results within: 3.5 hours, two step procedure

Measuring range: 0 – 2850 pg/mL

Sample volume: 100 μL

Stability: $18 \text{ months at } 2 - 8^{\circ} \text{ C}$

Incubation temperature: 20 – 25° C

Detection: 450 nm

Precision above 100 pg/mL: ≤10% CV within assay

Find out more

Scan the QR-code below to visit our website to find more information about CanAg Glypican-3 EIA.



Kit Components			
ltem	Quantity	Item	Quantity
Microplate, 96 wells streptavidin coated	1 plate, 12 x 8, breakable 1 x 5 mL, Liquid 1 x 1 mL, Lyophilized	Controls Glypican-3 Control 1 Glypican-3 Control 2 Biotin Anti-Glypican-3 Tracer, HRP Anti-Glypican-3 Tracer Diluent TMB HRP Substrate Stop Solution	1 x 1 mL, Lyophilized
Calibrators Glypican-3 Calibrator A Glypican-3 Calibrator B Glypican-3 Calibrator C Glypican-3 Calibrator D Glypican-3 Calibrator E			1 x 1 mL, Lyophilized 1 x 8 mL 1 x 0.75 mL 1 x 15 mL 1 x 12 mL 1 x 15 mL
		Wash Concentrate	1 x 50 mL

About us

Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.

Fujirebio has a long-lasting tradition for developing high-quality routine and truly novel biomarkers. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states. Fujirebio's global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network.

CanAg Diagnostics AB, now Fujirebio Diagnostics AB, was founded in 1992 in Sweden. In 2006 they joined Fujirebio Diagnostics, to strengthen the company's product offerings, distribution network, and research and development capabilities.

Reference

- American Cancer Society. What Is Liver Cancer? Am Cancer Soc. 2019;(November 2009):1-6. https://www.cancer.org/cancer/liver-cancer/about/what-is-liver-cancer.html
- 2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. Published online 2021. doi:10.3322/caac.21660
- 3. Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front Oncol. 2020;10(November):1-9. doi:10.3389/fonc.2020.601710
- Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52(12):1898-1907. doi:10.1038/s12276-020-00527-1
- 5. Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. 2019;16(10):589-604. doi:10.1038/s41575-019-0186-y.A
- Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2495-2503. doi:10.1158/1055-9965.EPI-20-0005
- Zacharakis G, Aleid A, Aldossari KK. New and old biomarkers of hepatocellular carcinoma. Hepatoma Res. 2018;4(10):65. doi:10.20517/2394-5079.2018.76

Fujirebio Diagnostics AB Elof Lindälvsgata 13 SE-414 58 Göteborg Sweden +46 31 85 70 30 phone +46 31 85 70 40 fax info@fdab.com e-mail www.fdab.com website USA:
For Research Use Only

– not for use in diagnostic procedures

